Tony Coles elected to Regeneron board of directors
Dr. Coles was nominated to become a member of the Regeneron Board by Sanofi.
Dr. Coles is Chairman and Chief Executive Officer of Yumanity Therapeutics, a company focused on transforming drug discovery for neurodegenerative diseases.
Previously, Dr. Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, an oncology-focused biopharmaceutical company, which was acquired by Amgen in 2012.
Prior to joining Onyx in 2008, he was President, Chief Executive Officer and a member of the board of directors of NPS Pharmaceuticals.
Before joining NPS, Dr. Coles served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company and Vertex Pharmaceuticals.
He is a director of McKesson Corporation and Chairman of the Board of CRISPR Therapeutics. He is also a member of the board of trustees for Johns Hopkins Medicine.
Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a Research Fellow at Harvard Medical School.
He earned his M.D. from Duke University, a master's degree in public health from Harvard University and an undergraduate degree from Johns Hopkins University. ■
LATEST MOVES FROM New York
- AzurRx BioPharma appoints Vern Lee Schramm to board
- Nature's Bounty appoints Mark Gelbert as CSO
- Global Net Lease appoints Christopher J. Masterson as CFO
- Bristol-Myers Squibb appoints Saurabh Saha as SVP
- GAIN Capital appoints Joseph A. Schenk as chairman
More inside POST
FedEx Corporation Q1 income down 10% Earnings